SJX-653

· Sojournix, Inc.

Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for SJX-653, covering 2022-01-11 to 2022-01-11. Get the full timeline:

Most recent: Clinical Trial Update: Phase 2 Study of SJX-653 in Postmenopausal Women With Moderate to Severe Vasomotor Symptoms [Phase 2]